Related Experiment Video
Updated: Mar 14, 2026

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
TFP5 prevents 1-methyl-4-phenyl pyridine ion-induced neurotoxicity in mouse cortical neurons
Qi-Shan Zhang1, Yuan-Gao Liao1, Zhong Ji2
1Department of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China; Department of Neurology, Chenzhou First People's Hospital, Chenzhou, Hunan 423000, P.R. China.
Abstract:
The present study aimed to investigate the protective effect of a modified p5 peptide, TFP5, on 1-methyl-4-phenyl pyridine ion (MPP+)-induced neurotoxicity in cortical neurons and explore the therapeutic effect of TFP5 on Parkinson's disease (PD). MPP+ was applied to a primary culture of mouse cortical neurons to establish the cell model of PD. Neurons were divided into four groups: Control, model (MPP+), scrambled peptide (Scb) (Scb + MPP+) and TFP5 (TFP5 + MPP+) groups. Pretreatment with Scb or TFP5 was applied to the latter two groups, respectively, for 3 h, while phosphate-buffered saline was applied to the control and model groups. MPP+ was then applied to all groups, with the exception of the control group, and neurons were cultured for an additional 24 h. Neuron viability was evaluated using a Cell Counting kit-8 (CCK8) assay. To explore the mechanism underlying the protective effects of TFP5, the expression levels of p35, p25 and phosphorylated myocyte enhancer factor 2 (p-MEF2D) were determined by western blotting. Fluorescence microscopy showed that TFP5 was able to pass through cell membranes and distribute around the nucleus. CCK8 assay showed that neuronal apoptosis was dependent on MPP+ concentration and exposure time. Cell viability decreased significantly in the model group compared with the control group (55±7 vs. 100±0%; P<0.01), and increased significantly in the TFP5 group compared with the model group (98±2 vs. 55±5%; P<0.01) and Scb group (98±2 vs. 54±4%; P<0.01). Scb exhibited no protective effect. Western blotting results showed that MPP+ induced p25 and p-MEF2D expression, TFP5 and Scb did not affect MPP+-induced p25 expression, but TFP5 reduced MPP+-induced p-MEF2D expression. In summary, TFP5 protects against MPP+-induced neurotoxicity in mouse cortical neurons, possibly through inhibiting the MPP+-induced formation and elevated kinase activity of a cyclin-dependent kinase 5/p25 complex.
Insights
The modified peptide TFP5 effectively protected mouse cortical neurons from 1-methyl-4-phenyl pyridine ion (MPP+) induced neurotoxicity. TFP5 may offer a therapeutic strategy for Parkinson's disease by inhibiting specific protein complex formation.
Area of Science:
- Neuroscience
- Molecular Biology
- Pharmacology
Background:
- Parkinson's disease (PD) is a neurodegenerative disorder characterized by the loss of dopaminergic neurons.
- 1-methyl-4-phenyl pyridine ion (MPP+) is a neurotoxin commonly used to model PD in vitro.
- Identifying neuroprotective agents is crucial for developing effective PD therapies.
Purpose of the Study:
- To investigate the protective effect of a modified peptide, TFP5, against MPP+-induced neurotoxicity in cortical neurons.
- To explore the potential therapeutic application of TFP5 in Parkinson's disease models.
Main Methods:
- Primary mouse cortical neurons were exposed to MPP+ to induce neurotoxicity.
- Neurons were treated with TFP5 or a scrambled peptide (Scb) prior to MPP+ exposure.
- Cell viability was assessed using a Cell Counting kit-8 (CCK8) assay.
- Protein expression levels of p35, p25, and phosphorylated myocyte enhancer factor 2 (p-MEF2D) were analyzed via western blotting.
Main Results:
- MPP+ significantly reduced neuronal viability in a dose- and time-dependent manner.
- TFP5 pretreatment significantly increased neuronal viability compared to MPP+-treated and Scb-treated groups.
- TFP5 reduced the expression of p-MEF2D, a downstream target potentially involved in neurotoxicity.
- Scrambled peptide (Scb) showed no significant protective effect.
Conclusions:
- TFP5 demonstrates significant neuroprotective effects against MPP+-induced neurotoxicity in vitro.
- The mechanism may involve the inhibition of MPP+-induced p-MEF2D expression.
- TFP5 holds promise as a potential therapeutic agent for Parkinson's disease.

